Strattera (atomoxetine) is the first NON-stimulant approved for attention-deficit hyperactivity disorder (ADHD) in Canada

February 2005

Strattera (atomoxetine) is the first NON-stimulant approved for attention-deficit hyperactivity disorder (ADHD) in Canada.

Unlike stimulants used for ADHD (Ritalin, Dexedrine), Strattera isn't a controlled drug and won't likely be abused.

Strattera blocks the reuptake of norepinephrine, which regulates attention, impulsivity, and activity.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

what to do about COX-2 inhibitors and other NSAIDs
Asthma updated guidelines for treating asthma during pregnancy
Strattera (atomoxetine) is the first NON-stimulant approved for attention-deficit hyperactivity disorder (ADHD) in Canada
Health Canada just approved memantine (Ebixa) for moderate to severe Alzheimer's disease
protease inhibitor called Telzir
Supplements Airborne is in high demand
Supplements DHEA for weight loss
Women's Health a unique new oral contraceptive called Yasmin
Women's Health Oral contraceptives may be less effective in overweight women
Cardiology More cardiologists will monitor C-reactive protein (CRP) levels
Cardiology the need to improve monitoring of patients on amiodarone (Cordarone)
Kidney Disease if aluminum in antiperspirants is harmful
Diabetes a new hemoglobin A1C test for HOME use called ChoiceDM A1C Home Test
Fibromyalgia what really works for fibromyalgia
Hematology & Oncology Evista (raloxifene) can help prevent breast cancer in postmenopausal women with osteoporosis
"Pharmacist Awareness Week" is Mar 7-13
Practice annual chart of new drugs approved by Health Canada in 2004